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Abstract
Background: Endovascular or intra-arterial treatment (IAT) increases the likelihood of recanalization in patients with
acute ischemic stroke caused by a proximal intracranial arterial occlusion. However, a beneficial effect of IAT on
functional recovery in patients with acute ischemic stroke remains unproven. The aim of this study is to assess the
effect of IAT on functional outcome in patients with acute ischemic stroke. Additionally, we aim to assess the safety
of IAT, and the effect on recanalization of different mechanical treatment modalities.
Methods/design: A multicenter randomized clinical trial with blinded outcome assessment. The active comparison
is IAT versus no IAT. IAT may consist of intra-arterial thrombolysis with alteplase or urokinase, mechanical treatment
or both. Mechanical treatment refers to retraction, aspiration, sonolysis, or use of a retrievable stent (stent-retriever).
Patients with a relevant intracranial proximal arterial occlusion of the anterior circulation, who can be treated within
6 hours after stroke onset, are eligible. Treatment effect will be estimated with ordinal logistic regression (shift analysis);
500 patients will be included in the trial for a power of 80% to detect a shift leading to a decrease in dependency in
10% of treated patients. The primary outcome is the score on the modified Rankin scale at 90 days. Secondary
outcomes are the National Institutes of Health stroke scale score at 24 hours, vessel patency at 24 hours, infarct
size on day 5, and the occurrence of major bleeding during the first 5 days.
Discussion: If IAT leads to a 10% absolute reduction in poor outcome after stroke, careful implementation of
the intervention could save approximately 1% of all new stroke cases from death or disability annually.
Trial registration: NTR1804 (7 May 2009)/ISRCTN10888758 (24 July 2012).
Keywords: Alteplase, Urokinase, Endovascular treatment, Acute ischemic stroke, Randomized controlled trial,
Stent, Thrombectomy
Background
Intravenous thrombolysis
Treatment with intravenous (IV) alteplase, aiming at early
reperfusion, has been proven effective for patients with
acute ischemic stroke when they are treated within
4.5 hours after stroke onset. The number of patients eligible
for treatment with IV alteplase is limited because of the
restricted time window [1-3]. In approximately 33% of the
patients with acute anterior circulation ischemic stroke,
symptoms are caused by a proximal occlusion of one of the
major intracranial arteries - that is, the distal intracranial
carotid artery, the proximal segment of the middle cerebral
artery and the anterior cerebral artery [4]. The likelihood of
a proximal occlusion increases with severity of neurological
deficit at presentation [5,6]. In these patients the effect of
IV alteplase is limited and leads to recanalization in only
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33% of the cases. In patients without recanalization
outcome is generally poor [7].
Intra-arterial treatment
Delivery of the thrombolytic agent at the site of the
occlusion may improve the likelihood of recanalization,
reperfusion of still viable tissue and, hence, recovery of
neurological deficits. Several randomized clinical trials of
intra-arterial treatment (IAT) for acute ischemic stroke
have been conducted and published [8-10]. Although the
results of these trials suggested a benefit, they have to be
interpreted with care and cannot be extrapolated to the
current clinical situation since IV alteplase was not an
option, neither as pre-treatment nor as part of the con-
trol treatment. In the Middle cerebral artery Embolism
Local fibrinolytic intervention Trial, mechanical treatment
was allowed [10], but this was not available in Prolyse
in Acute Cerebral Thromboembolism (PROACT) I or
PROACT II [8,9].
The Interventional Management of Stroke III (IMS-III)
trial was an international randomized, multicenter, open
label trial of the effect of combined IV/IAT versus IV
treatment only, when treatment is initiated within 3 hours
in patients with a National Institutes of Health stroke scale
(NIHSS) score ≥10. The sponsor terminated the trial pre-
maturely because of futility; there were no safety concerns.
The IMS-III included 656 patients who were all treated
intravenously. The increase in absolute risk of good out-
come (modified Rankin Scale (mRS) ≤2) at 3 months
follow-up was 1.5% (95% CI −6.1 to 9.1%). Several factors
may have contributed to the absence of a treatment effect:
confirmation of occlusion was not required at the time of
randomization; in the IV/IAT group, 23% of the patients
did not receive IAT due to the absence of an arterial oc-
clusion; time from onset of symptoms to IAT was rather
long (249 minutes on average); and only five patients
(1.2%) were treated with a stent-retriever [11].
SYNTHESIS Expansion was a head-to-head comparison
of IAT with IV treatment in 362 patients. In the interven-
tion group, 4.4% fewer patients recovered (95% CI −14.6
to 5.8%) than in the group with standard treatment. Time
from onset of symptoms to treatment was on average
225 minutes in the IAT group, but patients receiving the
standard treatment with IV recombinant tissue Plasmino-
gen Activator (rtPA) were treated 60 minutes earlier. In
this study, confirmation of an occlusion at the time of
randomization was not required and only a small group of
patients was treated with a stent-retriever (23 patients,
12.7%) [12].
Intravenous and intra-arterial thrombolytic treatment
The combination of IV and intra-arterial alteplase has
been described in observational studies and in one other
randomized controlled trial [13]. Some studies adjusted
the intravenous dose to 0.6 mg/kg, with a maximum
dose of 60 mg. The incidence of hemorrhages was no
larger than in studies of treatment with IV thrombolysis
only [14-18]. In case series, IAT with low dose intra-
arterial alteplase was preceded by full dose IV alteplase
(that is, 0.9 mg/kg). Risk of symptomatic intracerebral
hemorrhage ranged from 0 to 13% [19-21]. These studies
suggest that, in patients who have been treated this way,
recanalization rates can be high without unacceptably high
risks of complications.
Mechanical thrombectomy
The Mechanical Retrieval and Recanalization of Stroke
Clots Using Embolectomy trial compared mechanical
thrombectomy with the MERCI Retriever (Concentric
Medical, Mountain View, USA) with standard therapy
in 118 patients who had undergone IV thrombolysis. All
patients underwent computed tomography (CT) perfusion
or magnetic resonance imaging (MRI) diffusion/perfusion,
and randomization was stratified for the presence of
penumbra. This study showed no beneficial effect of the
intervention overall, or in the pre-stratified subgroup of
patients with penumbra [22].
Since the first application of IAT for acute ischemic
stroke, new techniques for mechanical treatment have
been developed. Mechanical treatment is a promising
approach, either as a primary intervention or as secondary
treatment in patients who fail IV thrombolysis, or in pa-
tients for whom thrombolytic agents are contraindicated.
Mechanical techniques include retraction, aspiration,
stenting and other techniques, such as local ultrasound-
augmented fibrinolysis. Studies suggest that, in experi-
enced hands, mechanical thrombectomy devices can be
safe and may lead to substantial recanalization rates
[23]. The results of two randomized clinical trials com-
paring retrievable stents with a retraction device suggest
that use of a retrievable stent leads to recanalization
more often than use of a retraction device. No comparison
was made with standard treatment [24,25].
Research question
The MR CLEAN aims to assess the effect of IAT on
functional outcome in patients with acute ischemic stroke
caused by a proximal intracranial arterial occlusion.
Methods/design
Design
The Multicenter Randomized Clinical trial of Endovascu-
lar treatment for Acute ischemic stroke in the Netherlands
(MR CLEAN) is a multicenter clinical trial with ran-
domized treatment allocation, open-label treatment and
blinded endpoint evaluation (PROBE design) (Figure 1).
The active comparison is IAT (intra-arterial alteplase or
urokinase, and/or mechanical treatment) versus no IAT.
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The treatment is provided in addition to best medical
management according to national and international guide-
lines, and may include IV thrombolysis. The study currently
runs in 17 large hospitals in the Netherlands for a total
period of 5 years (4 years of patient inclusion). Patient in-
clusion started in December 2010.
Patient inclusion and exclusion criteria
Patients aged 18 years or older with acute ischemic stroke
and a symptomatic anterior proximal artery occlusion,
which can be treated within 6 hours after stroke onset, are
eligible for participation in this trial.
General inclusion criteria are: a clinical diagnosis of
acute stroke with a deficit on the NIHSS of at least 2
points, CT or MRI ruling out intracranial hemorrhage,
occlusion of distal intracranial carotid artery or middle
(M1 or M2 or anterior cerebral artery (A1) demonstrated
with CT angiography (CTA), magnetic resonance angiog-
raphy (MRA) or digital subtraction angiography (DSA), the
possibility to start treatment within 6 hours of onset, aged
18 years or over and informed consent given in writing.
We use three sets of exclusion criteria: general exclusion
criteria for IAT, a specific exclusion criterion for mechanical
treatment and specific exclusion criteria for intra-arterial
thrombolysis.
General exclusion criteria are: arterial blood pressure
exceeding 185/110 mmHg, blood glucose less than 2.7
or over 22.2 mmol/L, treatment with IV thrombolysis in
a dose exceeding 0.9 mg/kg or 90 mg or treatment with
IV thrombolysis despite contraindications, and, finally,
cerebral infarction in the distribution of the relevant
occluded artery in the previous 6 weeks.
A specific exclusion criterion for intended mechanical
thrombectomy is laboratory evidence of coagulation
abnormalities (that is, platelet count <40 × 109/L, acti-
vated partial Thromboplastin time (APTT) >50 seconds
or International normalized ratio (INR) >3.0).
Specific exclusion criteria for intended intra-arterial
thrombolysis are: a history of cerebral hemorrhage, se-
vere head injury (contusion) in the previous 4 weeks and
clinical laboratory evidence of coagulation abnormalities,
(that is, platelet count <90 × 109/L, APTT >50 seconds
or INR >1.7), or treatment with oral thrombin or factor
X antagonists.
These hierarchically ordered exclusion criteria make it
possible that patients with contraindications for IV or IAT
with alteplase but no contraindication for mechanical
thrombectomy are included in the study. Also, patients
who cannot be treated within the 4.5-hour time window
may still be included in the trial. Enrolment was not lim-
ited according to the Alberta Stroke Program Early CT
Score (ASPECTS) or extension of early signs of infarction
at baseline.
Eligibility criteria for participating centers
To be fully eligible for participation in the trial and to
include patients in the trial, centers should meet the fol-
lowing minimum criteria. The intervention team should
have ample experience with intra-arterial interventions
for cerebrovascular disease (carotid stenting or aneurysm
coiling), peripheral artery disease, or coronary artery
disease. In order to include and randomize patients
who may be treated with mechanical thrombectomy,
the intervention team should make use of one or more
of the devices that have been approved by the trial
steering committee. Other devices are not allowed into
the trial. At least one member of the intervention team
should have sufficient experience with IAT for acute
ischemic stroke and with the particular device that is
being used (sufficient experience in this context is
defined as the completion of at least five procedures with
the particular device or procedure). Compliance with
these criteria is checked by the data-monitor.
Randomization
The randomization procedure is computer- and web-based,
using permuted blocks. Full-time back-up by telephone is
provided. Randomization is allowed when the intracranial
occlusion has been established by CTA, MRA or DSA.
Randomization is stratified for center, use of IV alteplase,
planned treatment modality (mechanical thrombectomy
or not) and stroke severity (NIHSS >14 or not).
Intervention
IAT will consist of arterial catheterization with a micro-
catheter to the level of occlusion and delivery of a
thrombolytic agent and/or mechanical thrombectomy.
The decision for intubation or conscious sedation was
left to the treating physicians. Time from onset to treat-
ment (needle in groin) was recorded. The trial steering
committee has issued recommendations that interventional
Figure 1 Trial logo.
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procedures should be stopped at 8 hours from onset of
symptoms.
Both alteplase and urokinase for intra-arterial thromb-
olysis are allowed into the trial, a dose of 1 mg alteplase is
considered to be equivalent to 10,000-15,000 U urokinase.
Patients who are pre-treated with IV alteplase should not
receive more than 30 mg alteplase or 400,000 U urokinase
intra-arterially. The maximum allowed dose of urokinase
is 1,200,000 U urokinase [26]. Mechanical treatment may
consist of thrombus retraction, aspiration, sonolysis or use
of a retrievable stent. Specific recommendations with
regards to procedures and devices will be issued regularly
by the trial steering committee.
The steering committee will make recommendations
for dosages of thrombolytic agents, procedures, and for
devices that will be allowed in the trial based on proposals
by the executive committee or local investigators. The
requirements for a device to be allowed in the trial are
Conformité Européenne (CE) marking or Food and Drug
Administration (FDA) registration, documented evidence
of safety in experienced hands, recanalization rates that
are similar to rates with other mechanical devices, and
published case series of at least 20 patients with one par-
ticular type of device in a representative series of patients.
Blinding
Both patient and treating physician will be aware of the
treatment assignment. Treatment assignment cannot be
determined before inclusion and randomization. Infor-
mation on outcome at 3 months will be assessed with
standardized forms and procedures, in a structured
telephone interview by an experienced research nurse
at the central trial office who is not aware of treatment
allocation. Assessment of outcome on the mRS will be
based on this information, by assessors who are blind to
the allocated and actually received treatment. Results of
neuroimaging will also be assessed by blinded observers.
Information on treatment allocation and primary outcome
will be kept separate from the main study database. The
steering committee will be kept unaware of the results of
interim analyses of outcomes, efficacy and safety. The trial
statistician (HL) will combine data on treatment allocation
and outcomes in order to report to the data monitoring
committee (DMC).
Study outcomes
The primary outcome is the score on the mRS at 90 days.
Secondary outcomes are the imaging parameter vessel
recanalization at 24 hours (Clot Burden score and collat-
eral score), infarct size at 5 days assessed with ASPECTS,
and final infarct volume calculation [27]. For clinical out-
come, the NIHSS and NIH supplemental motor scale [28]
at 24 hours and at 1 week or discharge will be assessed.
To further assess functional outcome at 90 days, the score
on the EuroQol 5D measurement tool for health-related
quality of life and Barthel index will be used (Table 1)
[29,30]. DSA runs are evaluated by a separate independent
central core laboratory because the assessors of DSA will
not be blinded to treatment allocation.
Safety aspects
Safety is an issue of concern, as experience with the
intervention overall and within the participating centers
is limited. Adverse events are undesirable experiences
occurring to subjects during the study, whether or not
they are considered to be related to the experimental
treatment. All adverse events reported spontaneously by
the subject or observed by the investigators are recorded.
A serious adverse event is defined as any untoward occur-
rence or effect that causes death, is life-threatening, re-
quires prolonged hospitalization or results in persistent
significant disability. The primary safety parameter will be
neurologic deterioration during the first 24 hours from
inclusion. This is defined as an increase in NIHSS of
4 points or more. Expected serious adverse events
are neurologic deterioration, symptomatic intracranial
hemorrhage, extracranial hemorrhage, technical complica-
tions or vascular damage at the target lesion, such as
perforation or dissection, distal emboli in non-involved
arteries, aspiration pneumonia, and allergic reactions to
contrast agents.
Data monitoring committee
The DMC is chaired by a neurologist, and includes a
neuro-interventionist and a statistician (see Appendix 1).
The DMC meets at least annually, and is provided with
structured unmasked reports, prepared by the trial statisti-
cian, for their eyes only. The DMC assesses the occur-
rence of unwanted effects by center and by allocated
Table 1 Clinical assessment and neuroimaging at baseline
and follow-up
Baseline
Clinical assessment Demographics, risk factors, medication,
medical history, NIHSS
Neuro-imaging Unenhanced CT and CT angiography*
Follow-up
Clinical assessment at 24 hours NIHSS. Adverse events.
Neuro-imaging at 24 hours CT angiography*
Neuro-imaging at 5-7 days Unenhanced CT or MRI
Clinical assessment at 1 week
or discharge
NIHSS; Barthel index
Clinical assessment at 90 days Modified Rankin score, Barthel index,
EQ5D
*Magnetic resonance imaging (MRI) and magnetic resonance angiography
(MRA) are allowed; computed tomography (CT) perfusion is recommended but
not obligatory. EQ-5D, EuroQol 5D measurement tool for health-related quality
of life; NIHSS, National Institutes of Health stroke scale.
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treatment. During the period of intake to the study, in-
terim analyses of mortality and of any other information
that is available on major endpoints (including serious
adverse events believed to be due to treatment) will be
supplied, in strict confidence, to the chairman of the
DMC along with any other analyses that the Committee
may request. In the light of these analyses, the DMC will
advise the chairman of the Steering Committee if, in their
view, the randomized comparisons in MR CLEAN have
provided both (1) "proof beyond reasonable doubt" that
for all, or for some specific types of patients, one particu-
lar treatment is clearly indicated or clearly contraindicated
in terms of a net difference in outcome, and (2) evidence
that might reasonably be expected to materially influence
patient management. Appropriate criteria of proof beyond
reasonable doubt cannot be specified precisely, but a
difference of at least 3 standard deviations in an interim
analysis of a major endpoint may be needed to justify halt-
ing, or modifying, the study prematurely. This criterion
has the practical advantage that the number of interim
analyses is of little importance.
There are no detailed safety stopping rules. Safety
criteria for individual centers include the following. If
the local investigator or other member of the team at a
trial center has a concern about the outcome of their
trial procedures, they should inform the MR CLEAN
trial office, which will organize a blinded assessment of
the relevant outcome events. This will be submitted by
the central office to the chairman of the DMC, who
may recommend further action, such as suspending
randomization at the center. Similarly, the database
manager at the trial office will monitor outcome events
and if there are three consecutive deaths or three consecu-
tive serious adverse events at a single center within 30 days
of treatment in the same arm of the study, then assess-
ment of the events will be triggered. A cumulative death
rate of more than 50% or a cumulative serious adverse
event rate exceeding 20% over 10 cases during hospital
admission would also trigger careful assessment of the
relevant outcome events.
Statistical analyses
Baseline characteristics will be summarized by means of
simple descriptive statistics. The main analysis of this
trial consists of a comparison of the primary outcome
after 90 days between the trial treatment groups. The
analysis will be based on the intention-to-treat principle.
The primary effect parameter takes the whole range of
the mRS into account and is defined as the relative risk
for improvement on the mRS. It is estimated as an odds
ratio with ordinal logistic regression [31,32]. In this
primary analysis, multivariable regression analysis will be
used to adjust for chance imbalances in main prognostic
variables between intervention and control group, such
as age, stroke severity (NIHSS), time since onset, previous
stroke, atrial fibrillation, carotid top occlusion and dia-
betes mellitus. Accordingly, treatment effect modification
will be explored in subgroups defined by (tertiles of) these
prognostic variables.
Secondary effect parameters will be the improvement
according to the classic dichotomizations of the mRS
scale at 0-1 versus 2-6 and 0-2 versus 3-6, vessel patency
on CTA, MRA or DSA at 24 hours, and the score on
the NIHSS at 24 hours and 1 week or discharge.
For the analysis of the secondary outcomes, simple
2 × 2 tables, two-group t-tests, Mann–Whitney tests,
and multivariable linear and logistic regression models
will be used, where appropriate. In all analyses, statistical
uncertainty will be expressed by means of 95% CI. A
detailed statistical analysis plan can be found in Additional
file 1.
Sample size
A moderate effect on the distribution of mRS scores,
resulting in a 10% absolute increase in the cumulative
proportion of patients with mRS 0-3 in the intervention
group is assumed, compared with controls. The distribu-
tion of outcome categories is based on the results of the
PROACT-II trial [9]. A total study size of 500 patients
(2 × 250 patients) allows for a power (1-abeta) of 82% at
a significance level of 0.05, taking into account 10%
cross-over rate [33]. This sample size should also be suffi-
cient to assess the effect of the intervention on secondary
endpoints: analysis of a meaningful reduction on NIHSS
at 1 week of 3-4 points (Cohen’s d = 0.33) would require a
sample of 400 patients, assuming that at 24 to 48 hours
mean NIHSS would be 12, with a standard deviation of
10. A doubling of the recanalization rate from 30% to 60%
would require 126 patients to achieve a power of 0.90.
Study organization and funding
See Appendix 1 for the study investigators. The trial
steering committee is the main decision-making body. It
consists of local principal investigators, a stroke neurolo-
gist and a neuro-interventionist from each participating
center, the members of the executive committee, and the
trial statistician. The steering committee meets at least
once a year. The trial executive committee consists of a
team of six principal investigators, the three coordinat-
ing junior researchers and the trial statistician. The trial
executive committee also forms the writing committee
for the trial. Publications will be made on behalf of all
investigators.
All incoming data are reviewed by the trial coordinator
at the central trial office. Imaging data are reviewed at
the secondary imaging center. All data were entered into
a web-based trial management system that allowed for
edit and audit trails, by trained local research nurses. All
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local data were carefully reviewed and first three, as
well as every 10th patient case report form was fully
checked against source data. Subcommittees exist for
outcome assessment, adverse event adjudication and
imaging assessment.
Ethical considerations
Informed consent will be obtained from all participants
or their legal representative, in writing, before inclusion
in the trial. The MR CLEAN trial protocol has been ap-
proved for the Netherlands by the central medical ethics
committee and research board of Erasmus MC University
Medical Center (MEC-2010-041).
Discussion
MR CLEAN is a pragmatic multicenter randomized clinical
trial of IAT for acute ischemic stroke versus no IAT. The
study is a pragmatic phase III trial with a PROBE design.
This trial will primarily evaluate the effect of IAT on func-
tional outcome; secondarily it will assess the safety of IAT,
and recanalization rates. MR CLEAN also aims to collect
data for a cost-effectiveness evaluation. Furthermore, this
trial will provide a basis for the further implementation of
IAT in the Netherlands and other countries.
For the trial results to be generalizable and representative
of the state-of-the-art approach in IAT, the trial design is
pragmatic. This implies the possibility to use several local
thrombolytic agents and mechanical devices for a broad
range of patients with acute ischemic stroke caused by a
proximal thrombo-embolic occlusion of one of the intra-
cranial arteries belonging to the anterior circulation.
The trial’s pragmatism is also apparent from the clinical
situations it addresses: patients who have been treated
unsuccessfully with IV thrombolysis, patients who can be
treated within 6 hours, but do not meet the time window
requirements for IV thrombolysis, and patients with
contraindications for IV or intra-arterial thrombolytic
treatment (thrombectomy only).
This trial’s design is based on the existence of clinical
equipoise, meaning that there is genuine uncertainty in
the expert medical community over whether IAT will be
beneficial [34]. The trial design accommodates the grey
area of uncertainty principle; we allow different ranges
of uncertainty with regard to eligibility related to age,
stroke severity and other clinical or radiological criteria.
We presume that all grey areas eventually overlap and will
allow us to analyze the full clinical spectrum of acute
ischemic stroke caused by intra-arterial occlusion [35].
Limitations and concerns
We estimated a sample size of 500 patients. Although
the sample size seems rather small, especially for a phase
III intervention trial, it allows us to estimate the primary
effect parameter with sufficient precision. Indeed, we
made a quite conservative estimate of the treatment
effect (10% absolute reduction in death and dependence),
which is similar in size to the average effect of IV
alteplase.
We do not restrict the use of multiple IAT modalities
per patient. This is a limitation of the trial design,
because it will restrict the possibilities of comparing
different treatment modalities and only allows us to give
a global judgment whether or not IAT is effective. On
the other hand, this pragmatism allows us to follow
current practice closely, and allows new mechanical devices
and treatment strategies into the trial, even after the start of
the study.
A concern with phase III trials of new interventions is
the possibility of a “learning curve” - that is, an increase
in effectiveness or decrease in the occurrence of
procedure-related complications during the conduct of
the trial. We therefore required a certain amount of
experience with intra-arterial interventions from each
group of devices and the number of procedures done
by the interventionist. Moreover, we carefully gathered
information on consecutive patients treated in each
center before the start of the trial, in order to document
the experience with the procedures. These data will be
used to test for the presence of a learning curve in the trial
data and before the start of the trial. Also, all participating
centers register consecutive patients with acute ischemic
stroke and record IATs given outside the trial protocol.
These will be reported [36].
Time since onset is a serious concern. The arguments
for a 6-, or even 8-hour time window from onset of
stroke symptoms to treatment are mostly based on trad-
ition (previous studies of IAT also used this window),
and the absence of an association of complications and
treatment effect with time since onset in previous, mostly
neutral trials. However, we consider it likely that a treat-
ment effect, if present, will be stronger in patients who
can be treated early after onset of symptoms and we will
encourage our investigators to act accordingly.
The primary effect parameter is defined as the relative
risk for improvement on the mRS estimated as an odds
ratio with ordinal logistic regression. The method is also
called “shift analysis”, as it takes changes along the full
range of the modified Rankin scale into account [31,32].
It is therefore more sensitive to differences in outcome
between the intervention and control groups, and also
more relevant, as improvements will be taken into con-
sideration that would not be registered as such in an
analysis of dichotomized outcomes.
We assess recanalization on CTA because it is available
in intervention and control patients. We will use a
combination of Clot Burden Score and collateral flow
score to assess the presence and extent of recanalization,
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because Thrombolysis in Myocardial Infarction (TIMI) or
Thrombolysis in Cerebral Infarction (TICI) scores do not
apply, as they require information concerning flow,
which is not provided by CTA. We do not repeat DSA
at 24 hours, as this would pose an additional risk to the
patients in the study.
MR CLEAN has started in the Netherlands. We see
no problems in generalizing our results to other coun-
tries in Western Europe and beyond. We strive to col-
laborate with other investigators and combine our data
in a systematic review for effect estimates and prognostic
modeling.
Other ongoing trials
Several randomized clinical trials of intra-arterial therapy
for acute ischemic stroke are ongoing. One trial exclu-
sively concerns the treatment of patients with basilar
artery occlusion [37]. Several other studies compare
mechanical thrombectomy with standard treatment,
both including, or preceded by IV alteplase [37-42].
Several other trials include patients who are ineligible
for IV alteplase treatment exclusively [43] or addition-
ally [44,45]. Several trials have an upper age limit
[39,38,42,43,45,46], some exclude patients with a large
ischemic core [44-46], and some require perfusion
mismatch on baseline imaging [41,45,46].
Compared to these ongoing trials, MR CLEAN has the
advantage of a short time window for inclusion and
treatment and no restrictions in age, stroke severity or in
penumbral imaging, all of which have not been validated
sufficiently in our view. Moreover, the intervention is not
restricted to one type or make of mechanical device.
Expected benefit
In the Netherlands more than 44,000 patients suffer
from stroke each year, 80% of these concern ischemic
stroke. About a third of these patients arrive within
6 hours in a hospital. Of these, we expect about 33% to
have a proximal intracranial occlusion [4]. A positive
trial result could lead to at least a 10% absolute reduction
in poor outcome. This implies that after successful imple-
mentation of the treatment in routine practice, almost
10% of all stroke patients could be treated and benefit. For
the Netherlands, more than 400 patients would thus be
saved from death or a disabled life, but for Europe as a
whole this could amount to more than 10,000 patients
annually [47].
We expect that MR CLEAN will increase our know-
ledge of the effects of IAT for acute ischemic stroke, and
facilitate the further development and implementation of
this potentially beneficial treatment.
Trial status
Patient recruitment started in December 2010. Inclusion
was completed with 500 patients on 16 March 2014
(Figure 2).
Figure 2 Observed and expected accrual. As of 16 March 2014, 500 patients were included in the trial.
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Appendix 1: The MR CLEAN investigators
Local principal investigators
Diederik W Dippel, Patrick A Brouwer, Erasmus MC
Rotterdam; Yvo B Roos, Charles B Majoie, Academisch
Medisch Centrum Amsterdam; Robert J van Oostenbrugge,
Wim H van Zwam, Maastricht UMC. Jelis Boiten, Geert J
Lycklama à Nijeholt, MC Haaglanden Den Haag; Marieke J
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